Contraindicated (one)bortezomib will boost the stage or outcome of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Potent or reasonable CYP2C19 inhibitors may perhaps improve mavacamten systemic exposure, resulting in heart failure as a result of systolic dysfunction. levoketoconazole will raise the degree or influence of bortezomib by influencing hepatic/i... https://cgp-2037692356.vidublog.com/26392708/the-single-best-strategy-to-use-for-lp-pla2-in-1